GenFlow Biosciences develops gene therapies utilizing the SIRT6 gene variant associated with centenarians to slow or reverse the aging process in humans and dogs. This approach aims to extend healthspan and lifespan, reducing healthcare costs and addressing the challenges of an aging population.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Aging leads to a decline in cellular function and an increased susceptibility to age-related diseases in both humans and animals. Current therapeutic options offer limited ability to directly address the underlying biological mechanisms of aging.
Solution
Genflow Biosciences is developing gene therapies that target the aging process by delivering a variant of the SIRT6 gene, which is associated with longevity in centenarians. Their lead compound, GF-1002, aims to slow or reverse the effects of aging at a cellular level, potentially extending both healthspan and lifespan. By intervening directly in the aging process, Genflow's therapies seek to reduce healthcare expenditures and alleviate the emotional and social challenges associated with an aging population. The company is focused on developing and commercializing these therapies for both human and veterinary applications.
Target Audience
The primary target audience includes individuals and pet owners seeking to extend healthspan and lifespan, as well as healthcare providers and veterinary professionals interested in innovative anti-aging therapies.
Features
- Utilizes a centenarian variant of the SIRT6 gene to enhance cellular function and promote longevity.
- Gene therapy approach delivers the SIRT6 gene variant to target cells.
- Developing therapies for both human and canine applications.
- Aims to delay or halt the onset of aging-related diseases.